1,673 material Form 8-K filings that 1,260 companies we cover made with the SEC in February 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Molina Healthcare said it expects a non-cash, pre-tax impairment charge of about $93 million on certain intangible assets in the first quarter of 2026, tied to its decision to exit the Medicare Advantage Prescription Drug product for 2027. The company also amended its credit agreement with Truist Bank as administrative agent, temporarily lowering the minimum interest coverage ratio it must maintain, which gives it more room under the covenant through September 2027.
Estimated non-cash, pre-tax impairment charge of about $93 million on certain intangible assets, to be recorded in Q1 2026
Charge results from exiting the Medicare Advantage Prescription Drug product for 2027, which the company says does not fit its focus on dual eligible members in Medicare
First Amendment to Credit Agreement dated February 4, 2026, with Truist Bank as administrative agent; minimum interest coverage ratio cut from 3.00:1.00 to 1.75:1.00 through December 31, 2026, then rising to 2.75:1.00 by September 30, 2027
The charge will be excluded from adjusted net income, as defined in the fourth quarter earnings release issued February 5, 2026
Eaton entered into an $8 billion senior unsecured delayed draw term loan on February 6, 2026, with a December 31, 2026 maturity. The same day, the company's $3 billion revolving credit agreement was increased to $4 billion. The filing says the new term loan can be drawn in a single draw on the closing date, and that the company will pay ticking fees on the undrawn amount starting 60 days after February 6, 2026. For shareholders, this adds up to $8 billion in committed borrowing that the company may draw on, and the filing does not state the purpose of the funds.
$8 billion senior unsecured delayed draw term loan dated February 6, 2026, maturing December 31, 2026, with Citibank as administrative agent
Revolving credit commitments increased from $3 billion to $4 billion under a Commitment Increase Agreement, on terms otherwise unchanged
Ticking fees apply from 60 days after February 6, 2026 until the earlier of maturity or funding, based on Eaton's senior unsecured debt ratings from S&P and Moody's
Karman Holdings completed its acquisition of Seemann Composites and Materials Sciences on February 3, 2026, for $210 million in cash plus $10 million in common stock, subject to adjustments. The company also amended its credit agreement, refinancing $502.8 million of term loans at a rate 75 basis points lower and adding $265 million, for a total term loan principal of $767.8 million, which funded the deal and added working capital.
Acquisition consideration: $210 million cash and $10 million in common stock, subject to customary purchase price adjustments
Term loans refinanced at $502.8 million and increased by $265 million to $767.8 million total principal
Term loan rate reduced 75 basis points to SOFR plus 2.75%; revolver pricing cut 75 basis points at each leverage level
Company expects the acquisitions to be immediately accretive in 2026 to revenue growth, EBITDA, earnings per share and cash flow
Hennessy Capital Investment Corp. VIII, a blank check company, closed its initial public offering on February 6, 2026, selling 24.15 million units at $10.00 each, including the full exercise of the underwriters' over-allotment option. The full $241.5 million of IPO proceeds was placed in a trust account, which generally stays there until a business combination is completed or shareholders redeem their shares, and the company has 24 months from closing to complete a combination.
IPO closed February 6, 2026: 24.15 million units at $10.00 per unit, for gross proceeds of $241.5 million
$241.5 million placed in a U.S. trust account administered by Odyssey; the company has 24 months from closing to complete an initial business combination
Sponsor HC VIII Sponsor LLC bought 671,000 private placement units for $6.71 million, with no underwriting discounts or commissions paid
Five directors appointed effective February 4, 2026, including Brian Bonner, Kyle Crowley, Javier Saade, Sandra Stash and Elizabeth Williams
Edgewell Personal Care closed the sale of its Feminine Care segment to Essity on February 2, 2026, receiving approximately $340 million in cash, subject to post-closing adjustments. The company plans to use the net proceeds mainly to pay down its U.S. revolving credit facility, and its pro forma filing estimates a loss on disposal and goodwill impairment of $42.1 million net of tax, which the company says may differ materially from the final figure.
Closing date was February 2, 2026; the company received about $340 million in cash from Essity, subject to adjustments for inventory, indebtedness and other items.
Pro forma filing shows $140.0 million outstanding on the revolving credit facility as of September 30, 2025, assumed to be repaid with sale proceeds.
Estimated loss on disposal and goodwill impairment of $42.1 million, net of tax, based on September 30, 2025 balances; the goodwill impairment alone was $37.4 million.
Transition services agreement with Essity covers accounting, IT, quality assurance, operations, supply chain and sales for at least one year.
Under Armour reported third-quarter fiscal 2026 revenue of $1.33 billion, down 5% from a year earlier, and a GAAP net loss of $431 million, which included a $247 million non-cash tax valuation allowance. The company also widened its fiscal 2026 GAAP operating loss outlook to about $154 million, while raising its adjusted diluted EPS outlook to $0.10 to $0.11 from $0.03 to $0.05, a non-GAAP measure that excludes charges. For shareholders, the GAAP results and outlook weakened even as the adjusted figures improved.
Revenue was $1.33 billion, down 5% from $1.40 billion; North America fell 10% to $757 million.
GAAP net loss was $431 million, or $1.01 per diluted share, including a $247 million valuation allowance on U.S. federal deferred tax assets.
Adjusted diluted EPS was $0.09, excluding a $99 million litigation reserve expense tied to an insurance carrier dispute.
Fiscal 2026 GAAP operating loss is now expected to be about $154 million, compared with the prior outlook of a $56 million to $71 million loss.
Cboe Global Markets reported record fourth-quarter 2025 net revenue of $671.1 million, up 28 percent, and diluted EPS of $2.97, up 60 percent from the prior-year quarter. The company also set 2026 guidance for mid single-digit organic total net revenue growth and adjusted operating expenses of $864 million to $879 million, which matters to shareholders as a baseline for the year ahead.
Q4 2025 net revenue $671.1 million, up 28 percent; adjusted diluted EPS $3.06, up 46 percent
Full-year 2025 diluted EPS $10.42, up 45 percent; full-year net revenue $2.4 billion, up 17 percent
2026 guidance: organic total net revenue growth 'mid single-digit'; adjusted operating expenses $864 million to $879 million
No share repurchases in Q4 2025; $614.5 million of buyback authorization remained at December 31, 2025
Piper Sandler reported record fourth-quarter 2025 net revenues of $666 million, up 38% from a year earlier, and full-year net revenues of $1.9 billion, up 24%. The board also declared a $5.00 special dividend and a $0.70 quarterly dividend, and approved a four-for-one forward stock split, which takes effect March 23, 2026.
Q4 2025 net revenues of $666 million, up 38% from Q4 2024; GAAP diluted EPS of $6.40
Full-year 2025 net revenues of $1.9 billion, up 24%; GAAP diluted EPS of $15.82 versus $10.24 in 2024
Special dividend of $5.00 and quarterly dividend of $0.70 per share, payable March 13, 2026 to holders of record March 3, 2026
Four-for-one forward split effective 4:30 p.m. ET March 23, 2026; split-adjusted trading begins March 24, 2026
Philip Morris International reported fourth-quarter and full-year 2025 results. Full-year reported diluted EPS was $7.26, up from $4.52 in 2024, and adjusted diluted EPS was $7.54, up 14.8%, while net revenues rose 7.3% to $40.6 billion. The company forecast 2026 reported diluted EPS of $7.87 to $8.02 and adjusted diluted EPS of $8.38 to $8.53.
Full-year 2025 reported diluted EPS of $7.26 versus $4.52 in 2024; adjusted diluted EPS of $7.54
Full-year 2025 net revenues of $40.6 billion, up 7.3% reported and 6.5% organically
2026 forecast: adjusted diluted EPS of $8.38 to $8.53, with no share repurchases assumed
Declared regular quarterly dividend of $1.47 per share, or $5.88 annualized
Biogen reported fourth quarter 2025 revenue of $2.3 billion, down 7%, and a GAAP diluted loss of $(0.33) per share, compared with GAAP EPS of $1.83 a year earlier. For full year 2025, revenue rose 2% to $9.9 billion and non-GAAP diluted EPS was $15.28, above the company's $14.50 to $15.00 guidance range, though down 7% from $16.47. The company expects 2026 non-GAAP diluted EPS of $15.25 to $16.25 and a mid-single digit percentage revenue decline.
Q4 2025 total revenue was $2,279 million, down 7% year-over-year; non-GAAP diluted EPS was $1.99 versus $3.44 in Q4 2024.
Full year 2025 total revenue was $9.9 billion, up 2%; GAAP diluted EPS was $8.79 and non-GAAP diluted EPS was $15.28.
Full year 2026 guidance: non-GAAP diluted EPS of $15.25 to $16.25 and total revenue expected to decline by a mid-single digit percentage versus 2025.
Q4 2025 included approximately $131 million of GAAP other expense related to litigation matters.
RXO reported a fourth-quarter 2025 GAAP net loss of $46 million, compared with $25 million a year earlier, with revenue down to $1.5 billion from $1.7 billion and adjusted EBITDA of $17 million versus $42 million. The company also closed a $450 million asset-based revolving credit facility on February 5, 2026, which replaces its prior $600 million facility, and expects first-quarter 2026 adjusted EBITDA of $5 million to $12 million.
Q4 2025 revenue was $1.5 billion versus $1.7 billion in Q4 2024; gross margin was 14.8% versus 15.5%
Q4 2025 GAAP net loss was $46 million, or $0.27 per diluted share, versus a net loss of $25 million, or $0.15 per share, a year earlier
Q4 2025 adjusted EBITDA was $17 million, down from $42 million; the GAAP loss included a $12 million goodwill impairment
Q1 2026 outlook: adjusted EBITDA of $5 million to $12 million, with Brokerage volume down 5% to 10% and gross margin of 11% to 13%
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.